サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1293756

ファーマコビジランス市場：タイプ別（アウトソーシング受託、インハウス）、臨床試験（第i相、第II相、第III相）、手法別、エンドユーザー別-2023-2030年の世界予測

Pharmacovigilance Market by Type (Contract Outsourcing, In-house), Clinical Trial (Phase I, Phase II, Phase III), Method, End User - Russia Ukraine Conflict and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 193 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ファーマコビジランス市場：タイプ別（アウトソーシング受託、インハウス）、臨床試験（第i相、第II相、第III相）、手法別、エンドユーザー別-2023-2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ファーマコビジランスの世界市場は、2023年に87億6,194万米ドル、CAGR 15.40%で大きく成長し、2030年には240億2,611万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のファーマコビジランス市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：ロシア・ウクライナ紛争、高インフレに関する包括的な理解を提供します。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.ファーマコビジランスの世界市場規模および予測は？

2.予測期間中、世界のファーマコビジランス市場を形成するCOVID-19の阻害要因と影響は？

3.ファーマコビジランスの世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.ファーマコビジランスの世界市場における競争戦略は？

5.ファーマコビジランスの世界市場における技術動向と規制の枠組みは？

6.ファーマコビジランスの世界市場における主要ベンダーの市場シェアは？

7.ファーマコビジランスの世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 慢性疾患の有病率の増加
      • 自発的レポートおよび電子医療記録（EHR）マイニングにおけるファーマコビジランスアプリケーションの増加
      • プレイヤー別アウトソーシングサービスの需要の高まり
      • ADRと薬物毒性の発生率の増加
    • 抑制要因
      • 中堅・中小企業向けの高コスト技術
    • 機会
      • 新型コロナウイルス感染症（COVID-19）の出現により新たな機会が開かれた
      • ヘルスケア企業別研究開発（R&D）への投資の増加
    • 課題
      • 熟練労働者の不足
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 ファーマコビジランス市場：タイプ別

  • 請負業務委託
  • 社内

第7章 ファーマコビジランス市場臨床試験別

  • フェーズI
  • フェーズ II
  • フェーズⅢ
  • フェーズ IV
  • 前臨床

第8章 ファーマコビジランス市場：方法別

  • コホートイベントのモニタリング
  • EHRマイニング
  • ADR報告の強化
  • 自発的な報告
  • 対象を絞った自発的な報告

第9章 ファーマコビジランス市場：エンドユーザー別

  • 学術調査機関
  • 政府機関
  • 健康保険会社
  • 病院と介護提供者
  • 製薬会社およびバイオテクノロジー企業

第10章 南北アメリカのファーマコビジランス市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域のファーマコビジランス市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカのファーマコビジランス市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第14章 掲載企業一覧

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. PHARMACOVIGILANCE MARKET RESEARCH PROCESS
  • FIGURE 2. PHARMACOVIGILANCE MARKET SIZE, 2022 VS 2030
  • FIGURE 3. PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
  • FIGURE 5. PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2022 VS 2030 (%)
  • FIGURE 6. PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2022 VS 2030 (%)
  • FIGURE 7. PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2022 VS 2030 (%)
  • FIGURE 8. PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 9. PHARMACOVIGILANCE MARKET DYNAMICS
  • FIGURE 10. PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 18. PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 19. PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. PHARMACOVIGILANCE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. PHARMACOVIGILANCE MARKET SIZE, BY CONTRACT OUTSOURCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 8. PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 14. PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20. PHARMACOVIGILANCE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. PHARMACOVIGILANCE MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. PHARMACOVIGILANCE MARKET SIZE, BY HEALTH INSURANCE COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. PHARMACOVIGILANCE MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. PHARMACOVIGILANCE MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 194. PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 195. PHARMACOVIGILANCE MARKET LICENSE & PRICING
目次
Product Code: MRR-43676CF420AF

The Global Pharmacovigilance Market is forecasted to grow significantly, with a projected USD 8,761.94 million in 2023 at a CAGR of 15.40% and expected to reach a staggering USD 24,026.11 million by 2030.

The the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Pharmacovigilance Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Pharmacovigilance Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Contract Outsourcing and In-house. The Contract Outsourcing commanded largest market share of 75.46% in 2022, followed by In-house.

Based on Clinical Trial, market is studied across Phase I, Phase II, Phase III, Phase IV, and Pre-clinical. The Phase IV commanded largest market share of 38.59% in 2022, followed by Phase III.

Based on Method, market is studied across Cohort Event Monitoring, EHR Mining, Intensified ADR Reporting, Spontaneous Reporting, and Targeted Spontaneous Reporting. The Spontaneous Reporting commanded largest market share of 27.55% in 2022, followed by Intensified ADR Reporting.

Based on End User, market is studied across Academic & Research Institutes, Government Agencies, Health Insurance Companies, Hospitals & Care Providers, and Pharma & Biotech Companies. The Pharma & Biotech Companies commanded largest market share of 49.80% in 2022, followed by Government Agencies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 37.17% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Pharmacovigilance Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Pharmacovigilance Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pharmacovigilance Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pharmacovigilance Market?

4. What is the competitive strategic window for opportunities in the Global Pharmacovigilance Market?

5. What are the technology trends and regulatory frameworks in the Global Pharmacovigilance Market?

6. What is the market share of the leading vendors in the Global Pharmacovigilance Market?

7. What modes and strategic moves are considered suitable for entering the Global Pharmacovigilance Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Pharmacovigilance Market, by Type, 2022 vs 2030
  • 4.3. Pharmacovigilance Market, by Clinical Trial, 2022 vs 2030
  • 4.4. Pharmacovigilance Market, by Method, 2022 vs 2030
  • 4.5. Pharmacovigilance Market, by End User, 2022 vs 2030
  • 4.6. Pharmacovigilance Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in the Prevalence of Chronic Diseases
      • 5.1.1.2. Rise in Pharmacovigilance Applications in Spontaneous Reporting and Electronic Health Record (EHR) Mining
      • 5.1.1.3. Rise in Demand for Outsourcing Services by Players
      • 5.1.1.4. Rising Incidence of ADR and Drug Toxicity
    • 5.1.2. Restraints
      • 5.1.2.1. High-cost Technology for Small and Mid-sized Players
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of COVID-19 have Opened New Opportunities
      • 5.1.3.2. Rising Investment in Research and Development (R&D) by Healthcare Companies
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of Skilled Labor
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Pharmacovigilance Market, by Type

  • 6.1. Introduction
  • 6.2. Contract Outsourcing
  • 6.3. In-house

7. Pharmacovigilance Market, by Clinical Trial

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III
  • 7.5. Phase IV
  • 7.6. Pre-clinical

8. Pharmacovigilance Market, by Method

  • 8.1. Introduction
  • 8.2. Cohort Event Monitoring
  • 8.3. EHR Mining
  • 8.4. Intensified ADR Reporting
  • 8.5. Spontaneous Reporting
  • 8.6. Targeted Spontaneous Reporting

9. Pharmacovigilance Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Government Agencies
  • 9.4. Health Insurance Companies
  • 9.5. Hospitals & Care Providers
  • 9.6. Pharma & Biotech Companies

10. Americas Pharmacovigilance Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pharmacovigilance Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pharmacovigilance Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing

1. Accenture, PLC

2. Bristol Myers Squibb

3. C.H. Boehringer Sohn AG & Ko. KG

4. Capgemini SE

5. ClinChoice Inc.

6. F. Hoffmann-La Roche AG

7. GlaxoSmithKline PLC

8. HCL Technologies Limited

9. ICON PLC

10. Infosys Limited

11. International Business Machines Corporation

12. IQVIA

13. ITclinical

14. Laboratory Corporation

15. Linical Co., Ltd.

16. Novartis International AG

17. Oracle Corporation

18. Parexel International

19. Pfizer Inc.

20. Quanticate International limited

21. Sanofi S.A.

22. Syneos Health, Inc.

23. Take Solutions Ltd.

24. Tata Consultancy Services

25. Wipro Limited